Sprint Bioscience AB (SPRINT) - Total Liabilities

Latest as of March 2026: Skr12.69 Million SEK ≈ $1.37 Million USD

Based on the latest financial reports, Sprint Bioscience AB (SPRINT) has total liabilities worth Skr12.69 Million SEK (≈ $1.37 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Sprint Bioscience AB annual equity growth to track the company's year-over-year net asset growth rate.

Sprint Bioscience AB - Total Liabilities Trend (2011–2025)

This chart illustrates how Sprint Bioscience AB's total liabilities have evolved over time, based on quarterly financial data. See SPRINT FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Sprint Bioscience AB Competitors by Total Liabilities

The table below lists competitors of Sprint Bioscience AB ranked by their total liabilities.

Company	Country	Total Liabilities
WT Financial Group Ltd AU:WTL	Australia	AU$26.32 Million
AbL Diagnostics SA PA:ABLD	France	€5.32 Million
Casing Macron Technology Co Ltd TWO:3325	Taiwan	NT$1.02 Billion
Wisher Industrial Co Ltd TW:1465	Taiwan	NT$175.85 Million
Zegona Communications Plc LSE:ZEG	UK	GBX6.41 Billion
Rodex Fasteners TWO:5015	Taiwan	NT$1.25 Billion
RAIZ Invest Ltd AU:RZI	Australia	AU$6.78 Million
Firetail Resources Ltd AU:FTL	Australia	AU$958.84K

Liability Composition Analysis (2011–2025)

This chart breaks down Sprint Bioscience AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sprint Bioscience AB (SPRINT) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	9.10	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.12	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.11	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sprint Bioscience AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sprint Bioscience AB (2011–2025)

The table below shows the annual total liabilities of Sprint Bioscience AB from 2011 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr17.48 Million ≈ $1.88 Million	-46.67%
2024-12-31	Skr32.78 Million ≈ $3.53 Million	-5.26%
2023-12-31	Skr34.60 Million ≈ $3.72 Million	+274.73%
2022-12-31	Skr9.23 Million ≈ $993.73K	+6.35%
2021-12-31	Skr8.68 Million ≈ $934.43K	-64.20%
2020-12-31	Skr24.25 Million ≈ $2.61 Million	+194.82%
2019-12-31	Skr8.23 Million ≈ $885.36K	-62.68%
2018-12-31	Skr22.05 Million ≈ $2.37 Million	+198.09%
2017-12-31	Skr7.40 Million ≈ $795.93K	-64.83%
2016-12-31	Skr21.03 Million ≈ $2.26 Million	-18.54%
2015-12-31	Skr25.81 Million ≈ $2.78 Million	+434.79%
2014-12-31	Skr4.83 Million ≈ $519.44K	+17.47%
2013-12-31	Skr4.11 Million ≈ $442.19K	+28.24%
2012-12-31	Skr3.20 Million ≈ $344.81K	+329.45%
2011-12-31	Skr746.09K ≈ $80.29K	--

About Sprint Bioscience AB

ST:SPRINT Sweden Biotechnology

Market Cap

$41.11 Million

Skr381.97 Million SEK

Market Cap Rank

#22598 Global

#431 in Sweden

Share Price

Skr3.62

Change (1 day)

+0.56%

52-Week Range

Skr0.56 - Skr4.49

All Time High

Skr47.75